RT Journal Article
SR Electronic
T1 Metabolic indicators associated with non-communicable diseases deteriorated in COVID-19 outbreak: evidence from a two-center, retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.02.20144857
DO 10.1101/2020.07.02.20144857
A1 Xue, Ting
A1 Xu, Lizhen
A1 Mao, Yaqian
A1 Lin, Wei
A1 Liang, Jixing
A1 Huang, Huibin
A1 Li, Liantao
A1 Wen, Junping
A1 Chen, Gang
YR 2020
UL http://medrxiv.org/content/early/2020/07/04/2020.07.02.20144857.abstract
AB Objective Our study aimed to investigate whether the metabolic indicators associated with non-communicable diseases (NCDs) in the general population have changed during the COVID-19 outbreak.METHODS This retrospective self-controlled study enrolled adult participants with metabolic indicators relate to NCDs followed at Fujian Provincial Hospital and Fujian Provincial Hospital South Branch. The metabolic indicators followed during January 1, 2020 and April 30, 2020, the peak period of the COVID-19 epidemic in China, were compared with the baseline value in the same period last year. Pared-samples T-test and Wilcoxon signed-rank test were performed to analyze the differences between paired data.Results The follow-up total cholesterol was significantly increased than that of the baseline (4.73 (4.05, 5.46) mmol/L vs 4.71 (4.05, 5.43) mmol/L, p=0.019; n=3379). Similar results were observed in triglyceride (1.29 (0.91, 1.88) vs 1.25 (0.87, 1.81) mmol/L, p<0.001; n=3381), uric acid (330.0 (272.0, 397.0) vs 327.0 (271.0, 389.0) umol/L, p<0.001; n=3364), and glycosylated hemoglobin (6.50 (6.10, 7.30) vs 6.50 (6.10, 7.20) %, p=0.013; n=532). No significant difference was observed in low density lipoprotein, body mass index and blood pressure.Conclusions Metabolic indicators associated with NCDs deteriorated in the COVID-19 outbreak. We should take action to prevent and control NCDs without delay.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Fujian Provincial HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this study are available upon request by contact with the corresponding author. ACE2angiotensin-converting-enzyme 2BMIbody mass indexBPblood pressureCOVID-192019 coronavirus diseaseDBPdiastolic blood pressureHbA1cglycosylated hemoglobinIQRinterquartile rangeLDLlow density lipoproteinNCDsnon-communicable diseasesSARS-CoV-2severe acute respiratory syndrome coronavirus 2SBPsystolic blood pressureTCtotal cholesterolTGtriglycerideUAuric acid